Drug intelligence / Profile preview

TJ087

Development stage: Preclinical
Lead developer: Taejoon Pharmaceutical
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Parenteral

Overview

TJ087 is an investigational small interfering RNA (siRNA) therapeutic being developed by Tuojie Biotech for the treatment of heart failure. Utilizing RNA interference (RNAi) technology, the drug is designed to silence the expression of a specific gene target involved in the pathophysiology and progression of heart failure. As of 2024, TJ087 is in the IND-enabling stage of development, with the sponsor focusing on completing the necessary preclinical studies to support an Investigational New Drug (IND) application for clinical trials.

Beyond the preview

Go deeper on TJ087.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJ087.

Explore the full profile